CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer.
Boumelha J, de Castro A, Bah N, Cha H, de Carné Trécesson S, Rana S, Tomaschko M, Anastasiou P, Mugarza E, Moore C, Goldstone R, East P, Litchfield K, Lee SH, Molina-Arcas M, Downward J.
Boumelha J, et al. Among authors: lee sh.
Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2627. Online ahead of print.
Cancer Res. 2024.
PMID: 38635884